Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 5Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Stomach Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Tongue Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Osteosarcoma 1Neoplasms, Plasma Cell 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1

Interventions

Sirolimus 9Everolimus 5Imatinib Mesylate 2temsirolimus 1saracatinib 1nintedanib 1carbon-11 acetate 1Valproic Acid 1Sugars 1Simvastatin 1Resveratrol 1Octreotide 1Loratadine 1Letrozole 1Immunoglobulin G 1Hydroxychloroquine 1Glutamine 1Doxycycline 1Disulfides 1Cetuximab 1Celecoxib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphangioleiomyomatosis × saracatinib × Clear all
NCT02116712 2016-11-30

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Baylor College of Medicine

Phase 1 Completed
9 enrolled

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡